Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.67
Quick Ratio3.55
Price-To-Earnings
Trailing P/E Ratio219.91
Forward P/E Ratio69.76
P/E Growth1.78
Sales & Book Value
Annual Sales$2.49 billion
Price / Sales17.77
Cash Flow$1.0378 per share
Price / Cash166.71
Book Value$8.08 per share
Price / Book21.41
Profitability
EPS (Most Recent Fiscal Year)$0.80
Net Income$263.48 million
Net Margins15.84%
Return on Equity19.86%
Return on Assets11.88%
Miscellaneous
Employees2,300
Outstanding Shares255,560,000
Market Cap$44.68 billion
Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions
What is Vertex Pharmaceuticals' stock symbol?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How will Vertex Pharmaceuticals' stock buyback program work?
Vertex Pharmaceuticals announced that its board has authorized a stock buyback program on Thursday, February 1st 2018, which permits the company to buyback $500,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's management believes its stock is undervalued.
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its earnings results on Wednesday, July, 25th. The pharmaceutical company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.40 by $0.54. The pharmaceutical company had revenue of $752.20 million for the quarter, compared to analysts' expectations of $680.86 million. Vertex Pharmaceuticals had a net margin of 15.84% and a return on equity of 19.86%. The company's revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.39 earnings per share. View Vertex Pharmaceuticals' Earnings History.
When is Vertex Pharmaceuticals' next earnings date?
What price target have analysts set for VRTX?
24 equities research analysts have issued 12 month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $103.00 to $230.00. On average, they expect Vertex Pharmaceuticals' stock price to reach $195.0455 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
What is the consensus analysts' recommendation for Vertex Pharmaceuticals?
24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 2 hold ratings and 22 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.
What are Wall Street analysts saying about Vertex Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Vertex’ efforts to get its two CF drugs — Kalydeco & Orkambi — approved for additional indications are encouraging. Positive data read-outs and regulatory approvals in 2017 increased the eligible patient population for its two CF drugs, Kalydeco & Orkambi, which backed sales growth. Vertex’s newly launched third CF medicine, Symdeko should be a significant contributor to growth in 2018. Symdeko is off to a strong start in the U.S. with an EU launch scheduled in the second half. Vertex’s CF pipeline is also quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth, as these have the potential to treat up to 90% of CF patients. The stock has outperformed the industry this year so far. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines." (6/30/2018)
- 2. Maxim Group analysts commented, "Vertex reported 1Q18 with revenue of $641M, beating consensus of $622M. Kalydeco revenue of $250M beat consensus of $230M, Orkambi/Symdeko revenue of $388M (Orkambi $354M, Symdeko $34M) beat consensus of $374M. Overall, total CF revenue was $638M, a y/y increase of 33%. Non-GAAP operating expenses were $360M and Non-GAAP EPS of $0.76 beat consensus $0.62. Vertex ended the period with $2.5B in cash." (4/27/2018)
- 3. HC Wainwright analysts commented, "Halts Triple Combination Trials in France as a Protest in Pricing Negotiations What’s new? We have recently learned via a twitter comment and associated article (http://bit.ly/2Bp7vL7) that Vertex has decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis (CF) in France. During the Vertex 4Q earnings call, management identified the two second-generation correctors that would be added to the combination of tezacaftor/ivacaftor to formulate the triple combination. It appears that these trials will continue in the US and other parts of Europe but will now be excluding France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. As mentioned in the article, this is a disappointment to the French CF patients that have been consistent participants in numerous trials to date and were eagerly awaiting more rapid access to what could be the most effective modulator treatment yet for CF." (2/13/2018)
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS) and Regeneron Pharmaceuticals (REGN).
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the folowing people:
- Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 62)
- Mr. Thomas Graney, CFO & Sr. VP (Age 53)
- Mr. Ian F. Smith, Exec. VP & COO (Age 52)
- Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 53)
- Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 43)
Has Vertex Pharmaceuticals been receiving favorable news coverage?
Press coverage about VRTX stock has trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media and rumor sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the pharmaceutical company an impact score of 46.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Vertex Pharmaceuticals.
Who are Vertex Pharmaceuticals' major shareholders?
Vertex Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.56%), FMR LLC (6.40%), Jennison Associates LLC (1.98%), Renaissance Technologies LLC (1.58%), Bank of New York Mellon Corp (0.91%) and Waddell & Reed Financial Inc. (0.87%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Margaret G Mcglynn, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.
Which institutional investors are selling Vertex Pharmaceuticals stock?
VRTX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, BlackRock Inc., Bank of Montreal Can, Atalanta Sosnoff Capital LLC, Morgan Stanley, Waddell & Reed Financial Inc. and Columbus Circle Investors. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.
Which institutional investors are buying Vertex Pharmaceuticals stock?
VRTX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., Standard Life Aberdeen plc, PointState Capital LP, OppenheimerFunds Inc., Marshall Wace LLP, Point72 Asset Management L.P. and Congress Asset Management Co. MA. View Insider Buying and Selling for Vertex Pharmaceuticals.
How do I buy shares of Vertex Pharmaceuticals?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals' stock price today?
One share of VRTX stock can currently be purchased for approximately $173.61.
How big of a company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $44.68 billion and generates $2.49 billion in revenue each year. The pharmaceutical company earns $263.48 million in net income (profit) each year or $0.80 on an earnings per share basis. Vertex Pharmaceuticals employs 2,300 workers across the globe.
How can I contact Vertex Pharmaceuticals?
Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]
MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
